Iloprost drugs is a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds.

Iloprost is a medication used to treat disorders such as pulmonary arterial hypertension, scleroderma, Raynaud syndrome, and others that cause constriction of blood vessels and poor blood flow in tissues. Ventavis or Ilomedine are the brand names for the medicine.

Iloprost dilates the constricted blood vessels (arteries) in the lungs, resulting in lower pulmonary blood pressure to the heart. The medicine can be administered via infusion or by inhaling it through nebulizers. The infusion is provided intravenously and lasts about six hours per day, with the session repeated three to five days in a row, whereas the inhalations should be done six to nine times each day, as prescribed by the physician.

Iloprost drugs is a medicine that is used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, and other conditions in which blood arteries become restricted and blood cannot flow to the tissues. This causes tissue damage and excessive blood pressure. It is now being studied as a frostbite therapy. Iloprost works by widening (dilating) blood vessels, allowing blood to flow again. It was created by the pharmaceutical company Schering AG and is marketed in Europe by Bayer Schering Pharma AG and in the United States by Actelion Pharmaceuticals. Iloprost is given via inhalation, and a therapeautic benefit of the drug is that a very low dose is required because of the deposition in the lung. Iloprost has few systemic side effects for that reason.

Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer. While Iloprost is an analog of PGI2 that activates PGI2's receptor, the Prostacyclin receptor, to stimulate vasodilation, it has little selectivity in that it binds to and activates all four receptors for prostaglandin E2 viz., Prostaglandin EP1 receptor, Prostaglandin EP2 receptor, Prostaglandin EP3 receptor, and Prostaglandin EP4 receptor. Activation of the EP2 and EP4 receptors cause vasodilation but activation of the EP3 receptor causes vasoconstriction.